Expert Review of Anti-infective Therapy最新文献_第4页

Diagnostic and clinical management of Candida auris infections in immunocompromised patients. 免疫功能低下患者耳念珠菌感染的诊断和临床管理。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-08-01 Epub Date: 2025-05-16 DOI: 10.1080/14787210.2025.2505567

Brunella Posteraro, Terenzio Cosio, Riccardo Torelli, Elena De Carolis, Carlotta Magrì, Patrizia Posteraro, Giulia De Angelis, Maurizio Sanguinetti

{"title":"Diagnostic and clinical management of Candida auris infections in immunocompromised patients.","authors":"Brunella Posteraro, Terenzio Cosio, Riccardo Torelli, Elena De Carolis, Carlotta Magrì, Patrizia Posteraro, Giulia De Angelis, Maurizio Sanguinetti","doi":"10.1080/14787210.2025.2505567","DOIUrl":"10.1080/14787210.2025.2505567","url":null,"abstract":"Introduction: Candida (Candidozyma) auris is an emerging fungal pathogen that poses a significant threat to immunocompromised patients. Its high mortality rates, resistance to multiple antifungal classes, and ability to spread rapidly in healthcare settings underscore the need for timely and accurate diagnosis to guide effective clinical management.Areas covered: This special report provides an updated overview of C. auris infections in immunocompromised hosts. It discusses current phenotypic and molecular diagnostic tools, antifungal susceptibility testing methods, and infection control strategies. Emerging therapies, including investigational antifungals and combination regimens, are also examined in light of evolving resistance patterns and clinical challenges.Expert opinion: Despite notable advances in diagnostics and treatment, major obstacles remain in the clinical management of C. auris, particularly in vulnerable populations. Barriers to guideline implementation, lack of standardized screening protocols, and limited access to novel antifungal agents continue to hinder effective response. Future efforts should focus on expanding diagnostic capacity, developing innovative therapies, and implementing targeted surveillance strategies to reduce the global burden of C. auris.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"561-570"},"PeriodicalIF":3.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the editor: "real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients". 致编辑的信：“在HIV合并感染患者中使用泛型方案治疗HCV感染的抗病毒治疗的实际有效性”。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-29 DOI: 10.1080/14787210.2025.2526848

Cuiming Sun, Ying Wen, Shi Tang

引用次数: 0

Real-world effectiveness and tolerability of post solid organ transplant patients with CMV switching from valganciclovir treatment to maribavir: analysis using lab-linked claims data in the United States. 实体器官移植后巨细胞病毒患者从缬更昔洛韦治疗转向马里巴韦治疗的实际有效性和耐受性：使用美国实验室相关索赔数据的分析

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-27 DOI: 10.1080/14787210.2025.2517344

Krithika Rajagopalan, Michael Bullano, Daniele Gelone, Tien Bo, Vamshidhar Taduka, Safiuddin Shoeb Syed

{"title":"Real-world effectiveness and tolerability of post solid organ transplant patients with CMV switching from valganciclovir treatment to maribavir: analysis using lab-linked claims data in the United States.","authors":"Krithika Rajagopalan, Michael Bullano, Daniele Gelone, Tien Bo, Vamshidhar Taduka, Safiuddin Shoeb Syed","doi":"10.1080/14787210.2025.2517344","DOIUrl":"10.1080/14787210.2025.2517344","url":null,"abstract":"Background: Antiviral (AV) treatment options (e.g. Valganciclovir, VGCV) for cytomegalovirus (CMV) infections present a challenging benefit-risk profile (e.g. bone-marrow suppression) and potentially increased resistance and refractoriness. Maribavir (MBV), a new AV treatment approved for refractory/resistant post-transplant CMV infections, demonstrated superior viral clearance in SOLSTICE trial.Research design and methods: A retrospective lab-linked claims analysis of solid organ transplant (SOT) patients on VGCV (≥900 mg BID) treatment who newly switched to MBV (i.e. index date) between 1 December 2021 and31 December 2023. MBV treatment effectiveness (CMV viremia clearance/no treatment switch) and tolerability (e.g. leukopenia) during 3-months pre- and post-index was examined.Results: Of the 1,247 post-SOT VGCV-treated patients, 81 switched to MBV; the mean age was 55 years, and 73% had kidney transplant. Among 33 with follow-up labs, 88% (n = 29) achieved viral clearance. Of the remaining 48 without follow-up labs, 60.4% (n = 29) did not switch to other AV treatments. The combined treatment effectiveness was 71.6%. Tolerability issues decreased after MBV initiation: with leukopenia, neutropenia, nausea, and diarrhea decreasing by 14.29%, 3.57%, 14.29%, and 17.86%, respectively.Conclusion: MBV-treated patients had 10-15% lower tolerability issues; over 7 in 10 demonstrated treatment effectiveness in this real-world analysis. MBV's favorable benefit-risk profile makes it a potentially valuable addition to the CMV treatment armamentarium.Clinical trial registration: www.clinicaltrials.gov identifier is NCT02931539.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"653-662"},"PeriodicalIF":3.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges associated with pertussis detection, monitoring, and vaccination in adults. 成人百日咳检测、监测和疫苗接种的相关挑战。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-08-01 Epub Date: 2025-07-09 DOI: 10.1080/14787210.2025.2516556

Annette K Regan

{"title":"Challenges associated with pertussis detection, monitoring, and vaccination in adults.","authors":"Annette K Regan","doi":"10.1080/14787210.2025.2516556","DOIUrl":"10.1080/14787210.2025.2516556","url":null,"abstract":"Introduction: Pertussis is a severe and potentially life-threatening disease, particularly for young children. Pertussis can have severe complications, including pneumonia, apnea, encephalopathy, rib fractures, and death, and globally, it is not well controlled. In 2019, there were 19.5 million cases of pertussis worldwide. Countries that transitioned from whole cell to acellular pertussis vaccine programs have reported increasing incidence of pertussis in adolescents and adults. Older adults and adults with chronic health conditions are more likely to experience severe pertussis-related illness.Areas covered: This review presents a summary of the evidence documenting diagnostic, surveillance, and vaccination challenges to controlling pertussis in adults. Searches of PubMed/Medline and clinicaltrials.gov were used to inform this review.Expert opinion: Based on the limited data available to document the burden of pertussis in adults, the true burden of disease in this population remains unknown. There is therefore a need for (1) stronger surveillance and increased awareness of pertussis in adults in high-income and low- and middle-income countries; (2) improved pertussis vaccines that can provide longer-lasting immunity and/or block transmission; and (3) enhanced efforts to increase pertussis vaccination in adults.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"639-650"},"PeriodicalIF":3.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Theranostic nanomaterials for scalp and hair fungal infections: advancing diagnosis and treatment amidst challenges. 治疗头皮和头发真菌感染的纳米材料：在挑战中推进诊断和治疗。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-08-01 Epub Date: 2025-07-09 DOI: 10.1080/14787210.2025.2526844

Mahendra Rai, Patrycja Golińska, Alina Sionkowska, Shubhangi Shirsat, Aniket K Gade, Avinash P Ingle, José Milton Elias de Matos, József Prokisch

{"title":"Theranostic nanomaterials for scalp and hair fungal infections: advancing diagnosis and treatment amidst challenges.","authors":"Mahendra Rai, Patrycja Golińska, Alina Sionkowska, Shubhangi Shirsat, Aniket K Gade, Avinash P Ingle, José Milton Elias de Matos, József Prokisch","doi":"10.1080/14787210.2025.2526844","DOIUrl":"10.1080/14787210.2025.2526844","url":null,"abstract":"Introduction: Fungal infections of the scalp and hair are usually caused by fungi like Trichophyton spp. Microsporum spp. and Malassezia furfur. These are major global health concerns but are often overlooked and misdiagnosed. Moreover, antimicrobial resistance and other challenges, like early detection methods, inefficient delivery of the antifungal agents, and their side effects, are important challenges in the treatment of such infections. These challenges can be overcome by using nanomaterials, which have been emerging as promising solutions.Area covered: Nanomaterials are reported to play a key role in combating scalp and hair infections caused by different fungi. This review highlights the major fungal infections of the scalp, conventionally used antifungal agents, nanomaterials used in diagnosis, nanocarriers for the delivery of drugs, the toxicity of nanomaterials, and safety.Expert opinion: Nanomaterials can inhibit the growth of emerging and existing pathogens, especially those resistant to conventional fungicides used to treat scalp and hair infections. The lower efficacy of current antifungal drugs has created a need for alternative antifungal strategies to treat these infections. In this context, nanomaterials offer promising potential as fungicidal agents that could be used alone or in combination with existing antifungals to combat scalp and hair infections more effectively.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"617-638"},"PeriodicalIF":3.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving debate around screening for Chlamydia trachomatis. 围绕沙眼衣原体筛查的不断演变的争论。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-27 DOI: 10.1080/14787210.2025.2526846

Barbara Van Der Pol

引用次数: 0

Can inhaled antifungals provide a viable solution for treatment-refractory pulmonary fungal infections? 吸入抗真菌药物能治疗难治性肺部真菌感染吗？

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-08-01 Epub Date: 2025-07-05 DOI: 10.1080/14787210.2025.2530624

Kazuhiro Ito

引用次数: 0

Lessons from the past: what does the future of clinical management of infection after solid organ transplantation look like? 过去的教训：实体器官移植后感染的临床管理的未来是什么样的？

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-02 DOI: 10.1080/14787210.2025.2513461

Mario Fernández-Ruiz, José María Aguado

{"title":"Lessons from the past: what does the future of clinical management of infection after solid organ transplantation look like?","authors":"Mario Fernández-Ruiz, José María Aguado","doi":"10.1080/14787210.2025.2513461","DOIUrl":"10.1080/14787210.2025.2513461","url":null,"abstract":"Introduction: Infection continues to be one of the most common complications after solid organ transplantation (SOT). Past years have witnessed major advances in the diagnosis, prevention and treatment of post-transplant infection. Nevertheless, controversial issues and unmet needs remain.Areas covered: We review recent contributions to the use of organs from hepatitis C or human immunodeficiency virus-positive donors or those with positive cultures for multidrug resistant organisms (MDROs), diagnostic next-generation sequencing, selective digestive decolonization (SDD), immune monitoring strategies for individualized risk assessment, vaccines and prophylactic monoclonal antibodies, and the prospects of adoptive T-cell immunotherapy and chimeric antigen receptor cell products. Based on these lessons, plausible future developments in the prevention and management of post-transplant infection are proposed.Expert commentary: We expect that current barriers for the acceptance of increased infection risk donors will be overcome, and that the arrival of new antibiotics will allow the use of organs from donors colonized or infected by MDROs. 'Pathogen-agnostic' high-throughput diagnostic approaches will progressively replace conventional microbiology methods. Prophylaxis will be individualized by means of peri-transplant SDD, a repertoire of immune biomarkers (including the changes in human virome), and passive pre-exposure immunization. Finally, advanced cellular therapies will become the standard care of SOT recipients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"541-559"},"PeriodicalIF":3.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The future of non-invasive azole antifungal treatment options for the management of vulvovaginal candidiasis. 无创唑抗真菌治疗外阴阴道念珠菌病的未来。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-13 DOI: 10.1080/14787210.2025.2516554

Guillermo Quindós, Cristina Marcos-Arias, Katherine Miranda-Cadena, Elena Sevillano, Nerea Jauregizar, José Schneider, Elena Eraso

{"title":"The future of non-invasive azole antifungal treatment options for the management of vulvovaginal candidiasis.","authors":"Guillermo Quindós, Cristina Marcos-Arias, Katherine Miranda-Cadena, Elena Sevillano, Nerea Jauregizar, José Schneider, Elena Eraso","doi":"10.1080/14787210.2025.2516554","DOIUrl":"10.1080/14787210.2025.2516554","url":null,"abstract":"Introduction: High worldwide prevalence and significant morbidity of vulvovaginal candidiasis (VVC) requires better therapeutic approaches to improve quality of life of affected women. Although treatment of acute episodes is often straightforward, complicated and recurrent vulvovaginal candidiasis (RVVC) presents medical challenges.Area covered: This review focuses on therapy of VVC particularly by topical antifungals , especially imidazoles, compared to oral treatment with fluconazole, itraconazole, ibrexafungerp, or oteseconazole. Candidiasis by non-Candida albicans, VVC in pregnant women and RVVC are complex challenges . Current treatment, alternatives, and roles played by topical azoles in VVC are highlighted.Expert opinion: VVC requires personalized treatment considering whether the woman is pregnant or not, concomitant treatments, clinical presentations (acute or recurrent) and the Candida species involved. Although therapeutic tools are increasing, the usefulness of topical drugs, such as clotrimazole and miconazole, is very relevant. In addition, we it is also necessary to expand the therapeutic tools with new antifungals and formulations, and repurposing current drugs against fluconazole-resistant species of Candida.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"571-584"},"PeriodicalIF":3.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From Data to Decisions: Leveraging Large, Real-World Databases to Guide Clinical Practice in C. difficile Infections. 从数据到决策：利用大型真实世界数据库来指导艰难梭菌感染的临床实践。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-31 DOI: 10.1080/14787210.2025.2541713

Kelly R Reveles, Kelsey A Strey

引用次数: 0